View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 3, 2018

Galapagos and MorphoSys begin IGUANA trial

Galapagos, in collaboration with MorphoSys, has started the IGUANA trial by screening the first patient of the trial.

Galapagos, in collaboration with MorphoSys, has started the IGUANA trial by screening the first patient of the trial.

IGUANA is a Phase II trial of MOR106 to treat patients with atopic dermatitis (AD).

The placebo controlled, double-blind trial is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MOR106.

Under the trial, around 180 patients with moderate-to-severe AD will be treated over a 12-week period with one of three different doses of MOR106 or placebo using two different dosing regimens across various centres in Europe.

"Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide."

The trial will investigate dosing at two or four-week intervals over the 12-week treatment period, which will be followed by a 16-week observation period.

The primary objective of the trial is the evaluation of percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12.

MorphoSys chief development officer Dr Malte Peters said: “Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide.

“We see a clear unmet medical need for additional safe and efficacious treatment options and we are looking forward to further developing MOR106 for these patients in the Phase II trial we have now initiated together with our partner Galapagos.”

MorphoSys has used its Ylanthia antibody platform to develop MOR106, which is based on a target discovered by Galapagos.

MOR106 is an investigational antibody directed against IL-17C, a cytokine expressed preferentially in the skin and has been implicated in dermal inflammation.

IL-17C is also shown to be distinct from other members of the IL-17 cytokine family.

MorphoSys is yet to confirm the safety and efficacy of MOR106.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU